Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22729331 | 0.98 | KMT2A (0.49) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24029781 | 0.88 | HDAC2 (0.48) | MEN1KMT2AALDH1A1DRD2DRD4 | |
| SCHEMBL12156373 | 0.85 | DRD4 (0.56) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL2746896 | 0.85 | LMNA (0.59) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL8135888 | 0.84 | DRD4 (0.55) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL21941875 | 0.81 | DRD4 (0.56) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL290746 | 0.81 | NPC1 (0.49) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL21017768 | 0.81 | DRD2 (0.59) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL13915568 | 0.79 | KMT2A (0.48) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL9807625 | 0.79 | NPC1 (0.54) | CA12CA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| CN-114599643-B | Aryl glucoside derivative | 上海喆邺生物科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114599643-A | Aryl glucoside derivative | 上海喆邺生物科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-111630058-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| WO-2021227439-A1 | ARYL GLUCOSIDE DERIVATIVE | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-111630058-A | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019149178-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | 广东东阳光药业有限公司 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | CA12 2578/4885CA1 3196/4885CA2 1133/4885 |
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | CA12 3608/4885CA1 4133/4885CA2 2060/4885 |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | CA12 2578/4885CA1 3196/4885CA2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.